US oncologyPub Date : 2010-01-01DOI: 10.17925/ohr.2010.06.0.9
Pascal Jean-Pierre
{"title":"Management of Cancer-related Cognitive Dysfunction-Conceptualization Challenges and Implications for Clinical Research and Practice.","authors":"Pascal Jean-Pierre","doi":"10.17925/ohr.2010.06.0.9","DOIUrl":"10.17925/ohr.2010.06.0.9","url":null,"abstract":"<p><p>Cancer-related cognitive dysfunction (CRCD)-especially impairments in attention and memory-constitutes a significant problem for cancer patients and survivors. Incidence rates of CRCD range from 17 to 75%. Cognitive impairment experienced by cancer patients can be severe and long-lasting. Strategies to ameliorate this condition have been hindered by difficulties in understanding the precise etiology of CRCD and a lack of consensus on appropriate and reliable assessment approaches. This article provides an overview of the magnitude of the problem and discusses pathophysiology, current theories, clinical presentation, assessment concerns, and management of CRCD.</p>","PeriodicalId":89517,"journal":{"name":"US oncology","volume":"6 ","pages":"9-12"},"PeriodicalIF":0.0,"publicationDate":"2010-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4397910/pdf/nihms591899.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33234482","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
US oncologyPub Date : 2009-01-01DOI: 10.17925/OHR.2010.06.0.20
K. Mustian, L. Peppone, O. Palesh, M. Janelsins, S. Mohile, J. Purnell, T. Darling
{"title":"Exercise and Cancer-related Fatigue.","authors":"K. Mustian, L. Peppone, O. Palesh, M. Janelsins, S. Mohile, J. Purnell, T. Darling","doi":"10.17925/OHR.2010.06.0.20","DOIUrl":"https://doi.org/10.17925/OHR.2010.06.0.20","url":null,"abstract":"Cancer-related fatigue is the most common side effect reported by cancer patients during and after treatment. Cancer-related fatigue significantly interferes with a patient's ability to perform activities of daily living and maintain functional independence and quality of life. Cancer-related fatigue can also interfere with a patient's ability to complete treatments. The purpose of this article is to provide an overview of cancer-related fatigue, its pathopsychophysiology, and the role of exercise in the management of this side effect.","PeriodicalId":89517,"journal":{"name":"US oncology","volume":"5 2 1","pages":"20-23"},"PeriodicalIF":0.0,"publicationDate":"2009-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67595524","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Karen M Mustian, Luke J Peppone, Oxana G Palesh, Michelle C Janelsins, Supriya G Mohile, Jason Q Purnell, Tom V Darling
{"title":"Exercise and Cancer-related Fatigue.","authors":"Karen M Mustian, Luke J Peppone, Oxana G Palesh, Michelle C Janelsins, Supriya G Mohile, Jason Q Purnell, Tom V Darling","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Cancer-related fatigue is the most common side effect reported by cancer patients during and after treatment. Cancer-related fatigue significantly interferes with a patient's ability to perform activities of daily living and maintain functional independence and quality of life. Cancer-related fatigue can also interfere with a patient's ability to complete treatments. The purpose of this article is to provide an overview of cancer-related fatigue, its pathopsychophysiology, and the role of exercise in the management of this side effect.</p>","PeriodicalId":89517,"journal":{"name":"US oncology","volume":"5 2","pages":"20-23"},"PeriodicalIF":0.0,"publicationDate":"2009-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3156559/pdf/nihms-263414.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"30086642","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
US oncologyPub Date : 2009-01-01DOI: 10.17925/ohr.2009.05.1.40
Adam Yagui-Beltrán, Lisa M Coussens, David M Jablons
{"title":"Respiratory Homeostasis and Exploitation of the Immune System for Lung Cancer Vaccines.","authors":"Adam Yagui-Beltrán, Lisa M Coussens, David M Jablons","doi":"10.17925/ohr.2009.05.1.40","DOIUrl":"10.17925/ohr.2009.05.1.40","url":null,"abstract":"<p><p>Lung cancer is the leading cause of all cancer deaths in the US. The international scientific and clinical community has made significant advances toward understanding specific molecular mechanisms underlying lung carcinogenesis; however, despite these insights and advances in surgery and chemoradiotherapy, the prognosis for non-small-cell lung cancer (NSCLC) remains poor. Nonetheless, significant effort is being focused on advancing translational research evaluating the efficacy of novel targeted therapeutic strategies for lung cancer. Illustrative examples of this include antagonists of the epidermal growth factor receptor (EGFR), tyrosine kinase inhibitors (TKIs) such as gefitinib and erlotinib, and a diverse assortment of anti-angiogenic compounds targeting growth factors and/or their receptors that regulate tumor-associated angiogenic programs. In addition, with the increased awareness of the significant role chronically activated leukocytes play as potentiators of solid-tumor development, the role of innate and adaptive immune cells as regulators of lung carcinogenesis is being examined. While some of these studies are examining how novel therapeutic strategies may enhance the efficacy of lung cancer vaccines, others are evaluating the intrinsic characteristics of the immune response to lung cancer in order to identify rate-limiting molecular and/or cellular programs to target with novel anticancer therapeutics. In this article, we explore important aspects of the immune system and its role in regulating normal respiratory homeostasis compared with the immune response accompanying development of lung cancer. These hallmarks are then discussed in the context of recent efforts to develop lung cancer vaccines, where we have highlighted important concepts that must be taken into consideration for future development of novel therapeutic strategies and clinical trials assessing their efficacy.</p>","PeriodicalId":89517,"journal":{"name":"US oncology","volume":"58 1","pages":"40-48"},"PeriodicalIF":0.0,"publicationDate":"2009-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3285551/pdf/nihms275657.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"30489919","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
US oncologyPub Date : 2008-01-01DOI: 10.17925/ohr.2008.04.1.19
Karen M Mustian, Tom V Darling, Michelle C Janelsins, Pascal Jean-Pierre, Joseph A Roscoe, Gary R Morrow
{"title":"Chemotherapy-Induced Nausea and Vomiting.","authors":"Karen M Mustian, Tom V Darling, Michelle C Janelsins, Pascal Jean-Pierre, Joseph A Roscoe, Gary R Morrow","doi":"10.17925/ohr.2008.04.1.19","DOIUrl":"https://doi.org/10.17925/ohr.2008.04.1.19","url":null,"abstract":"<p><p>Despite treatment advances, nausea and vomiting, especially anticipatory nausea and vomiting, delayed nausea and vomiting and nausea alone, are still the most common, expected and feared side effects among patients receiving chemotherapy. Of the 70 to 80% of cancer patients who experience chemotherapy-induced nausea and vomiting many will delay or refuse future chemotherapy treatments and contemplate stopping all treatments because of fear of further nausea and vomiting. The purpose of this chapter is to provide an overview of the patho-psychophysiology of CINV, the recommended guidelines for standard treatment, and highlight newer targeted treatment approaches.</p>","PeriodicalId":89517,"journal":{"name":"US oncology","volume":"4 1","pages":"19-23"},"PeriodicalIF":0.0,"publicationDate":"2008-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3994039/pdf/nihms543671.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"32286181","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
